Professor Lotery

In 2004 Professor Andrew Lotery was one of a team of researchers who discovered the first gene Andrew Pippet   to be linked to AMD.  This was a world-leading medical breakthrough and was published in the New England Journal of Medicine, one of the most prestigious medical publications in the world.  As a result of this breakthrough, Professor Lotery and his research team are hopeful that they will find a cure for AMD within the next 10 years, if sufficient funding is obtained.



The aims of Professor Lotery’s laboratory are the following:


  • To perform world class research to create better treatments and thus prevent blindness
  • To achieve this by attracting sufficient funding to allow the research to proceed quickly
  • To train the next generation of academic ophthalmologists and visual scientists
  • To disseminate our research findings in leading research journals
  • To work as a team to achieve these goals

Professor Lotery currently has several junior ophthalmologists training in the Gift of Sight Research Centre so that they too may become clinician scientists.  We are delighted that Dr Srini Goverdhan, a clinical ophthalmologist by training and who was Professor Lotery's first PhD student, has recently been awarded a nationally competitive Clinical Senior Lectureship Award (Higher Education Funding Council of England, July 2011). 

Professor Lotery also raises funds for his research by undertaking personal challenges.  For the latest of these please see our News and Events page.  To support Prof's fundraising please look at his 2011 Justgiving page.

 

To view Professor Andrew Lotery's University of Southampton School of Medicine CV and research details please follow this link 

 

For details of papers which have recently been published relating to eye research please see the Clinical Neurosciences website and look under 'Related pages' 'Publications'.

 

 

Future research

Glaucoma is also a major cause of blindness and treatments are limited and not always effective. Currently we have collected DNA samples from over 500 patients with primary open angle glaucoma. These patient samples will be used to identify novel glaucoma genes, drug targets and treatments.